S&P 500 7,703.30 ▲ 26.53 (+0.35%) DOW 52,309.44 â–ŧ 52.14 (-0.10%) NASDAQ 26,368.26 ▲ 198.88 (+0.76%) US Markets Open â€ĸ 10:49 AM ET

PPCB

Propanc Biopharma, Inc.

Price Chart
Latest Quote

$2.24

-0.05 (-2.18%)
Current Price
Previous Close $2.29
Open $2.24
Day High $2.29
Day Low $2.21
Volume 15,776
Fetched: 2026-10-27T14:49:30
Stock Information
Shares Outstanding 1.03M
Total Debt $509K
Cash Equivalents $832K
Net Income $-19.79M
Sector Healthcare
Industry Biotechnology
Market Cap $2.31M
EPS (TTM) $-176.20
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$1.13M
Income$-19.79M
Book/sh$28.40
Cash/sh$0.81
Employees2
Financial Ratios
Quick Ratio0.25
Current Ratio2.55
Debt/Eq5.42
Returns & Margins
ROA-70.14%
ROE-161.86%
Ownership
Insider Ownership38.12%
Institutional Ownership0.46%
Insider & Institutional transactions data not available
Valuation Ratios
P/B0.08
Analyst Data
Recommendationnone
Technical Indicators
SMA20$3.91
SMA50$7.28
SMA200$25.05
RSI7.75
ATR0.4376
Shares Float291K
Short Float1.30%
Short Ratio0.21
Volatility3.33
Rel Volume0.42
Performance History
Week-30.22%
Month-58.01%
Quarter-77.37%
6 Months-91.55%
YTD-98.43%
Year-99.41%
3 Years-72.00%
5 Years-99.99%
10 Years-100.00%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $2.24 15,776
2026-10-26 $2.29 103,800
2026-10-23 $2.80 26,770
2026-10-22 $2.74 20,770
2026-10-21 $3.15 5,860
2026-10-20 $3.21 11,140
2026-10-19 $3.17 22,550
2026-10-16 $3.42 205,210
2026-10-15 $3.41 16,510
2026-10-14 $3.66 82,570
2026-10-13 $4.12 33,340
2026-10-12 $4.40 19,560
2026-10-09 $4.86 18,930
2026-10-08 $4.71 19,470
2026-10-07 $4.99 87,800
2026-10-06 $4.91 18,780
2026-10-05 $5.00 9,070
2026-10-02 $5.07 7,200
2026-10-01 $5.01 8,290
2026-09-30 $4.94 13,140
2026-09-29 $5.12 14,390
2026-09-28 $5.33 42,160
About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of JaÊn, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

📰 Latest News
No news articles available at the moment. Check back later for updates on PPCB.
Period:
Loading...
Income Statement (Annual)
Metric 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Interest Expense $430,539 $563,757 $665,841 $532,821
Total Expenses $18,185,569 $57,278,131 $1,536,049 $1,776,645
Rent Expense Supplemental $40,932 $26,560 $34,150 $28,841
Other Income Expense $-246,763 $-1,081,421 $252,170 $-480,977
Other Non Operating Income Expenses $-326,000 - - -
Net Non Operating Interest Income Expense $-430,378 $-563,748 $-665,781 $-532,785
Interest Expense Non Operating $430,539 $563,757 $665,841 $532,821
Operating Expense $18,185,569 $57,278,131 $1,536,049 $1,776,645
General And Administrative Expense $17,560,092 $57,054,410 $1,287,947 $1,528,726
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-18,862,710 $-58,923,300 $-1,820,528 $-2,660,566
Net Interest Income $-430,378 $-563,748 $-665,781 $-532,785
Interest Income $161 $9 $60 $36
Normalized Income $-18,941,947 $-57,841,879 $-2,072,698 $-2,201,969
Net Income From Continuing And Discontinued Operation $-18,862,710 $-58,923,300 $-1,820,528 $-2,660,566
Total Operating Income As Reported $-18,185,569 $-57,278,131 $-1,536,049 $-1,776,645
Net Income Common Stockholders $-19,794,956 $-58,923,300 $-2,013,488 $-3,126,839
Net Income $-18,862,710 $-58,923,300 $-1,820,528 $-2,660,566
Net Income Including Noncontrolling Interests $-18,862,710 $-58,923,300 $-1,820,528 $-2,660,566
Net Income Continuous Operations $-18,862,710 $-58,923,300 $-1,820,528 $-2,660,566
Pretax Income $-18,862,710 $-58,923,300 $-1,949,660 $-2,790,407
Special Income Charges $133,071 $-871,032 $54,565 $43,468
Interest Income Non Operating $161 $9 $60 $36
Operating Income $-18,185,569 $-57,278,131 $-1,536,049 $-1,776,645
Per Share
Diluted EPS - $-371.22 $-6311.87 $-781709.75
Basic EPS - $-371.22 $-6311.87 $-781709.75
Other
Tax Effect Of Unusual Items $0 $0 $0 $-22,380
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-18,488,705 $-57,257,935 $-1,514,333 $-1,753,678
Total Unusual Items $79,237 $-1,081,421 $252,170 $-480,977
Total Unusual Items Excluding Goodwill $79,237 $-1,081,421 $252,170 $-480,977
Reconciled Depreciation $22,703 $20,187 $21,656 $22,931
EBITDA (Bullshit earnings) $-18,409,468 $-58,339,356 $-1,262,163 $-2,234,655
EBIT $-18,432,171 $-58,359,543 $-1,283,819 $-2,257,586
Diluted NI Availto Com Stockholders $-19,794,956 $-58,923,300 $-2,013,488 $-3,126,839
Otherunder Preferred Stock Dividend $932,246 $0 $192,960 $466,273
Tax Provision $0 $0 $-129,132 $-129,841
Other Special Charges $-133,071 $871,032 $-54,565 $-43,468
Gain On Sale Of Security $-53,834 $-210,389 $197,605 $-524,445
Research And Development $625,477 $223,721 $248,102 $247,919
Selling General And Administration $17,560,092 $57,054,410 $1,287,947 $1,528,726
Other Gand A $15,243,223 $33,731,460 $1,253,797 $1,499,885
Rent And Landing Fees $40,932 $26,560 $34,150 $28,841
Salaries And Wages $2,275,937 $23,296,390 - -
Diluted Average Shares - $158,727 $319 $4
Basic Average Shares - $158,727 $319 $4
Fetched: 2026-10-25
Balance Sheet (Annual)
Metric 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Assets
Net Tangible Assets $9,401,661 $13,906,192 $-3,779,059 $-3,117,179
Total Assets $12,779,912 $19,631,808 $72,365 $60,328
Total Non Current Assets $4,237,322 $11,278,992 $46,924 $41,289
Non Current Prepaid Assets $4,192,617 $10,927,806 $2,008 $1,999
Non Current Deferred Assets $0 $291,773 $27,117 $0
Current Assets $8,542,590 $8,352,816 $25,441 $19,039
Other Current Assets $34,923 $1,380 $1,406 $6,125
Prepaid Assets $7,661,967 $8,334,046 $0 $6,125
Receivables $13,694 $5,302 $2,950 $2,867
Taxes Receivable $13,694 $5,302 $2,950 $2,867
Cash Cash Equivalents And Short Term Investments $832,006 $12,088 $21,085 $10,047
Cash And Cash Equivalents $832,006 $12,088 $21,085 $10,047
Cash Financial $832,006 $12,088 $21,085 $10,047
Debt
Total Debt $509,116 $1,726,882 $948,271 $545,916
Long Term Debt And Capital Lease Obligation $23,818 $147,376 $58,642 $19,278
Current Debt And Capital Lease Obligation $485,298 $1,579,506 $889,629 $526,638
Current Debt $460,809 $1,561,842 $870,267 $505,133
Other Current Borrowings $460,809 $1,018,530 $665,573 $505,133
Net Debt - $1,655,381 $907,824 $495,086
Long Term Debt - $105,627 $58,642 -
Liabilities
Total Liabilities Net Minority Interest $3,378,251 $5,725,616 $3,851,424 $3,177,507
Total Non Current Liabilities Net Minority Interest $23,818 $147,376 $58,642 $19,278
Current Liabilities $3,354,433 $5,578,240 $3,792,782 $3,158,229
Current Notes Payable $0 $543,312 $204,694 $0
Payables And Accrued Expenses $2,115,097 $2,926,941 $2,129,896 $1,620,764
Interest Payable $128,318 $190,795 $94,612 $44,709
Payables $1,131,429 $1,249,596 $1,243,094 $996,348
Accounts Payable $1,131,429 $1,249,596 $1,213,335 $966,718
Other Current Liabilities - $403,892 $133,886 $423,209
Equity
Common Stock Equity $9,401,659 $13,906,192 $-3,779,059 $-3,117,179
Preferred Stock Equity $2 - - -
Total Equity Gross Minority Interest $9,401,661 $13,906,192 $-3,779,059 $-3,117,179
Stockholders Equity $9,401,661 $13,906,192 $-3,779,059 $-3,117,179
Gains Losses Not Affecting Retained Earnings $1,176,255 $1,318,917 $1,269,581 $1,294,876
Other Equity Adjustments $1,176,255 $1,318,917 $1,269,581 $1,294,876
Retained Earnings $-144,484,230 $-125,621,520 $-66,698,220 $-64,684,732
Other Equity Interest - - - -
Other
Ordinary Shares Number $3,310,827 $464,471 $319 $4
Share Issued $3,310,827 $464,471 $319 $4
Tangible Book Value $9,401,659 $13,906,192 $-3,779,059 $-3,117,179
Invested Capital $9,862,468 $15,573,661 $-2,850,150 $-2,612,046
Working Capital $5,188,157 $2,774,576 $-3,767,341 $-3,139,190
Capital Lease Obligations $48,307 $59,413 $19,362 $40,783
Total Capitalization $9,401,661 $14,011,819 $-3,720,417 $-3,117,179
Treasury Stock $46,477 $46,477 $46,477 $46,477
Additional Paid In Capital $152,752,314 $138,254,808 $61,696,049 $60,311,502
Capital Stock $3,799 $464 $8 $7,652
Common Stock $3,797 $464 $8 $7,652
Preferred Stock $2 $0 $0 $0
Long Term Capital Lease Obligation $23,818 $41,749 $0 $19,278
Current Capital Lease Obligation $24,489 $17,664 $19,362 $21,505
Pensionand Other Post Retirement Benefit Plans Current $754,038 $667,901 $639,371 $587,618
Current Accrued Expenses $983,668 $1,677,345 $886,802 $624,416
Net PPE $44,705 $59,413 $17,799 $39,290
Accumulated Depreciation $-54,946 $-93,992 $-73,945 $-52,343
Gross PPE $99,651 $153,405 $91,744 $91,633
Machinery Furniture Equipment $31,312 $25,078 $25,543 $25,432
Buildings And Improvements $68,339 $128,327 $66,201 $66,201
Properties $0 $0 $0 $0
Dueto Related Parties Current - $0 $29,759 $29,630
Treasury Shares Number - - $0 $0
Preferred Shares Number - - - -
Fetched: 2026-10-25
Cash Flow Statement (Annual)
Metric 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Free Cash Flow
Free Cash Flow $-5,687,568 $-405,168 $-935,118 $-1,105,251
Operating Activities
Operating Cash Flow $-5,682,635 $-405,168 $-935,118 $-1,105,251
Cash Flow From Continuing Operating Activities $-5,682,635 $-405,168 $-935,118 $-1,105,251
Operating Gains Losses $-41,787 $1,081,421 $27,541 $733,558
Investing Activities
Capital Expenditure $-4,933 - - -
Investing Cash Flow $-4,933 $0 - -
Cash Flow From Continuing Investing Activities $-4,933 $0 - -
Financing Activities
Issuance Of Capital Stock $4,264,557 $0 $23,057 $24,711
Financing Cash Flow $6,457,298 $490,756 $941,894 $1,113,719
Cash Flow From Continuing Financing Activities $6,457,298 $490,756 $941,894 $1,113,719
Net Preferred Stock Issuance $950,099 - - -
Preferred Stock Issuance $950,099 - - -
Net Common Stock Issuance $3,314,458 $0 $23,057 $24,711
Common Stock Issuance $3,314,458 $0 $23,057 $24,711
Net Other Financing Charges - $-264,656 - $23,758
Other
Repayment Of Debt $-1,060,508 $-130,788 $-142,909 $0
Issuance Of Debt $253,249 $886,200 $1,061,746 $590,250
Interest Paid Supplemental Data $131,687 $30,715 $9,491 $2,883
Income Tax Paid Supplemental Data $0 $0 $0 $0
End Cash Position $832,006 $12,088 $21,085 $10,047
Beginning Cash Position $12,088 $21,085 $10,047 $4,067
Effect Of Exchange Rate Changes $50,188 $-94,585 $4,262 $-2,488
Changes In Cash $769,730 $85,588 $6,776 $8,468
Proceeds From Stock Option Exercised $3,000,000 $0 $0 $475,000
Net Issuance Payments Of Debt $-807,259 $755,412 $918,837 $590,250
Net Short Term Debt Issuance $-700,127 $411,712 $614,141 $590,250
Short Term Debt Payments $-875,127 $-130,788 $-142,909 $0
Short Term Debt Issuance $175,000 $542,500 $757,050 $590,250
Net Long Term Debt Issuance $-107,132 $343,700 $304,696 $0
Long Term Debt Payments $-185,381 $0 - -
Long Term Debt Issuance $78,249 $343,700 $304,696 $0
Net PPE Purchase And Sale $-4,933 $0 - -
Purchase Of PPE $-4,933 $0 - -
Change In Working Capital $-584,938 $1,138,212 $417,418 $472,587
Change In Other Working Capital $51,476 $40,184 $24,196 $186,912
Change In Other Current Liabilities $-14,189 $-21,722 $-21,598 $-19,857
Change In Other Current Assets $-33,471 $0 - -
Change In Payables And Accrued Expense $-539,516 $1,120,776 $531,103 $303,960
Change In Accrued Expense $-356,504 $933,044 $288,695 $222,985
Change In Interest Payable $44,545 $255,155 $78,733 $92,474
Change In Payable $-183,012 $187,732 $242,408 $80,975
Change In Account Payable $-183,012 $187,732 $242,408 $80,975
Change In Prepaid Assets $-41,121 $1,379 $-116,212 $2,182
Change In Receivables $-8,117 $-2,405 $-71 $-610
Other Non Cash Items $5,285,605 $51,657,082 $297,837 $326,239
Stock Based Compensation $8,498,492 $4,621,230 $0 -
Depreciation Amortization Depletion $22,703 $20,187 $21,656 $22,931
Depreciation And Amortization $22,703 $20,187 $21,656 $22,931
Depreciation $22,703 $20,187 $21,656 $22,931
Gain Loss On Investment Securities $123,436 $121,146 $104,186 $765,412
Net Foreign Currency Exchange Gain Loss $-32,152 $89,243 $-22,080 $-5,885
Net Income From Continuing Operations $-18,862,710 $-58,923,300 $-1,820,528 $-2,660,566
Provisionand Write Offof Assets - $0 $120,958 $0
Amortization Of Securities - - - -
Fetched: 2026-10-25